Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 11/20 | 0.38 |
| ▸ | CCNH | P51946 | 11/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 11/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21096555 | 0.96 | CYP1A2 (0.36) | CDK7CCNHMNAT1ADORA2AACVR1 | |
| SCHEMBL21096681 | 0.87 | ACVR1 (0.35) | ADORA2AACVR1ADORA2BCYP1A2CYP2C9 | |
| SCHEMBL21096789 | 0.85 | ADORA2B (0.35) | ADORA2AACVR1ADORA2BCYP1A2CYP2C9 | |
| SCHEMBL21097153 | 0.83 | ADORA2B (0.40) | ADORA2AACVR1ADORA2B | |
| SCHEMBL21096551 | 0.81 | ADORA2B (0.41) | ADORA2AADORA2B | |
| SCHEMBL21096553 | 0.76 | GAA (0.39) | CDK7CCNHMNAT1ADORA2AADORA2B | |
| SCHEMBL21097146 | 0.70 | ADORA2A (0.37) | CDK7CCNHMNAT1ADORA2A | |
| SCHEMBL21096805 | 0.69 | ACVR1 (0.40) | ADORA2AACVR1ADORA2BCYP1A2CYP2C9 | |
| SCHEMBL21096552 | 0.68 | CYP1A2 (0.37) | ADORA2AACVR1ADORA2BCYP1A2CYP2C9 | |
| SCHEMBL21097167 | 0.67 | MAP3K14 (0.40) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | CDK7 594/4885CCNH 3731/4885MNAT1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.